IP Library › Granted Patent US 9,051,301
Granted Patent B2
US 9,051,301 · App. 11/229,922 · Granted Jun 9, 2015

Crystalline form of a drug

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,051,301
App. No.
11/229,922
Granted
Jun 9, 2015
Kind
B2
Abstract

Atrasentan Hydrochloride Crystalline Form 3, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.

Claims (1)

1. Atrasentan Hydrochloride Crystalline Form 3 characterized, when measured at about 25° C. with Cu-Kα radiation, by a powder diffraction pattern with peaks having respective 2θ values of about 6.7°, 8.4°, 15.6°, 18.0°, 18.5°, 19.8°20.6° and 21.95°.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030185/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2006
From: ZHANG, GEOFF G.Z.
To: ABBOTTLABORATORIES
Reel/Frame 018443/0824 →